ATE398619T1 - Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine - Google Patents

Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine

Info

Publication number
ATE398619T1
ATE398619T1 AT05792946T AT05792946T ATE398619T1 AT E398619 T1 ATE398619 T1 AT E398619T1 AT 05792946 T AT05792946 T AT 05792946T AT 05792946 T AT05792946 T AT 05792946T AT E398619 T1 ATE398619 T1 AT E398619T1
Authority
AT
Austria
Prior art keywords
cdk2
colon
breast
lung
treatment
Prior art date
Application number
AT05792946T
Other languages
English (en)
Inventor
Jin-Jun Liu
Kin-Chun Luk
Giacomo Pizzolato
Yi Ren
Kshitij Chhabilbhai Thakkar
Peter Wovkulich
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE398619(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE398619T1 publication Critical patent/ATE398619T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05792946T 2004-10-13 2005-10-04 Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine ATE398619T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61817404P 2004-10-13 2004-10-13

Publications (1)

Publication Number Publication Date
ATE398619T1 true ATE398619T1 (de) 2008-07-15

Family

ID=35311946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05792946T ATE398619T1 (de) 2004-10-13 2005-10-04 Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine

Country Status (25)

Country Link
US (1) US7524840B2 (de)
EP (1) EP1802625B1 (de)
JP (1) JP2008515939A (de)
KR (1) KR100858262B1 (de)
CN (2) CN101899049A (de)
AR (1) AR051326A1 (de)
AT (1) ATE398619T1 (de)
AU (1) AU2005293818A1 (de)
BR (1) BRPI0518152A (de)
CA (1) CA2582985A1 (de)
DE (1) DE602005007623D1 (de)
DK (1) DK1802625T3 (de)
ES (1) ES2308551T3 (de)
HR (1) HRP20080429T3 (de)
IL (1) IL182423A0 (de)
MX (1) MX2007004464A (de)
NO (1) NO20071794L (de)
NZ (1) NZ554353A (de)
PL (1) PL1802625T3 (de)
PT (1) PT1802625E (de)
RU (1) RU2394826C2 (de)
SI (1) SI1802625T1 (de)
TW (1) TWI309652B (de)
WO (1) WO2006040036A1 (de)
ZA (1) ZA200702973B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038215A1 (en) * 2005-09-22 2007-04-05 Incyte Corporation Tetracyclic inhibitors of janus kinases
BRPI0617252A2 (pt) * 2005-10-14 2011-07-19 Hoffmann La Roche regime de administração para benzodiazepina 5-2-clorofenil)-1,2-diidro-7-flìor-8-metóxi-3-metil-pira zolo [3,4-b] [1,4]
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (de) 2007-06-13 2016-03-23 Incyte Holdings Corporation Kristalline Salze des Janus-Kinasehemmers (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-YL)-1H-pyrazol-1-YL)-3-cyclopentylpropanenitril
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
NZ596479A (en) * 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP2011201794A (ja) * 2010-03-24 2011-10-13 Fujifilm Corp 5−アミノピラゾール誘導体及びその塩の製造方法
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
KR102242077B1 (ko) 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
EP3489239B1 (de) 2013-03-06 2021-09-15 Incyte Holdings Corporation Verfahren und zwischenprodukte zur herstellung eines jak-hemmers
MX376856B (es) 2013-08-07 2025-03-07 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
HUE050567T2 (hu) 2015-09-23 2020-12-28 Janssen Pharmaceutica Nv Triciklusos heterociklusok rák kezelésére
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CN106928040A (zh) * 2015-12-31 2017-07-07 上海医药工业研究院 Sglt2抑制剂中间体的制备方法
RU2019120162A (ru) * 2016-12-12 2021-01-12 Де Юниверсити Оф Сидней Непептидные агонисты рецепторов окситоцина
SI3447056T1 (sl) * 2016-12-13 2025-10-30 Transthera Sciences (Nanjing), Inc. Spojina, ki zavira multikinaze in njena kristalna oblika ter njena uporaba
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
KR20260080448A (ko) 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
BR112022022477A2 (pt) 2020-05-08 2022-12-13 Transthera Sciences Nanjing Inc Método para sintetizar composto antitumoral e intermediários do mesmo
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
WO2024039210A1 (ko) 2022-08-17 2024-02-22 한국화학연구원 Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681341A (en) * 1970-12-23 1972-08-01 Hoffmann La Roche Process for preparing 1-lower alkyl-1,4-benzodiazepin-2-ones
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
ZA889116B (en) * 1987-12-18 1989-08-30 Hoffmann La Roche Tricyclic compounds
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) * 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
TWI241302B (en) * 2000-12-01 2005-10-11 Ajinomoto Kk Lactam compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
RU2394826C2 (ru) 2010-07-20
TWI309652B (en) 2009-05-11
US7524840B2 (en) 2009-04-28
MX2007004464A (es) 2007-05-07
TW200628469A (en) 2006-08-16
SI1802625T1 (sl) 2008-10-31
CA2582985A1 (en) 2006-04-20
NO20071794L (no) 2007-07-10
WO2006040036A1 (en) 2006-04-20
HRP20080429T3 (en) 2008-09-30
CN101899049A (zh) 2010-12-01
AR051326A1 (es) 2007-01-03
ES2308551T3 (es) 2008-12-01
NZ554353A (en) 2010-01-29
PT1802625E (pt) 2008-08-06
EP1802625A1 (de) 2007-07-04
KR20070054243A (ko) 2007-05-28
KR100858262B1 (ko) 2008-09-11
PL1802625T3 (pl) 2008-12-31
BRPI0518152A (pt) 2008-11-04
RU2007117770A (ru) 2008-11-20
CN101039946B (zh) 2010-12-08
DK1802625T3 (da) 2008-09-01
EP1802625B1 (de) 2008-06-18
CN101039946A (zh) 2007-09-19
IL182423A0 (en) 2007-07-24
US20060079511A1 (en) 2006-04-13
AU2005293818A1 (en) 2006-04-20
DE602005007623D1 (de) 2008-07-31
HK1108284A1 (en) 2008-05-02
JP2008515939A (ja) 2008-05-15
ZA200702973B (en) 2009-09-30

Similar Documents

Publication Publication Date Title
DE602005007623D1 (de) Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine
IL258880A (en) Diarylhydantoin compounds
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
UA116188C2 (uk) Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
EP1667680A4 (de) Kombinationsverfahren zur behandlung von krebs
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
TW200740844A (en) Novel MAdCAM antibodies
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
ATE443991T1 (de) Verwendung von phenylsemicarbazonen für die saatgutbeizung
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
ATE491948T1 (de) Gpr30-östrogenrezeptor bei mammakarzinomen
ATE520402T1 (de) Anti-egfr-antikörper und vegfr-inhibitoren umfassende kombinationen für die behandlung von krebs
NO20070043L (no) Fremgangsmåte for behandling av Fischer-Tropsch-hydrokarboner
DK1962094T3 (da) Detektionsmiddel og terapeutisk middel til højmalign brystcancer
ITFI20030150A1 (it) Metodo per la diagnosi del carcinoma della mammella.
CY1116426T1 (el) Ενωσεις διαρυλυδαντοϊνης
TN2010000489A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
UA101464C2 (en) Phosphatidylinositol 3-kinase inhibitors and methods of their use
DE502006009303D1 (de) Acylglycerophospholipide zur behandlung von krebs-begleiterscheinungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1802625

Country of ref document: EP